InSilicoTrials’ Post

Words of wisdom from one of our key speakers Klaudia Eriksson Philipp from Pfizer for startups. What should you consider when you're looking to scale? Read her insights from the panel below!

Great first day at LSX - partnering for Life Science eXecutives conference in London. Not only had I chance to meet loads of inspiring leaders and funders but also to talk about healthtech at scale in Europe. Some key take aways for start-ups to consider when thinking of scaling to new markets: - what is the complexity of the regulatory/compliance/reimbursement systems - what is the level of the clincal evidence that will be needed to get an approval - what would be the level of hurdel to adoption/integretion of your solution - how many of similar solutions are already present in that market - what is the level of investement in form of money and time that will be needed to scale and in order to break even - can I partner up with i.e. pharma, to help me scale #lsx #london Thank you Chris Hamilton Lucy Jones Joao Barbosa da Silva Matthew Bardsley

Where are we today with decentralized clinical trial services, and what research on the financial value and return on investment of #DCTs are we starting to see occur in the field? Learn from our Commercial Executive Director of MRN Technologies, Edward Triebell, the overlooked potential of decentralized and hybrid clinical trials and how #patientcentric approaches can expedite studies and improve efficiency. Despite the clear benefits of digital innovation, why has the industry been slow to embrace these advancements? Click the link below to read more from Edwards article with Samedan Ltd https://lnkd.in/eW6C6VHf

Making clinical trials more accessible is crucial for improving health outcomes in diverse populations and advancing inclusive medical research. Our recent Site Spotlight sheds light on how EmVenio Research is using technology to achieve these goals. In an interview with Phillip Stanford, Senior Director, Applications & PMO at EmVenio, we explore their unique approach and its impact on underrepresented communities. EmVenio is setting up clinical trial sites in areas with limited research activity and leveraging advanced eClinical solutions, like RealTime-SOMS, to break down barriers and ensure diverse participation in clinical research. For a deeper look into EmVenio's innovative work and future plans, read the full interview here: https://lnkd.in/guM_jqjZ #SiteSpotlight #DiversityInResearch #ClinicalTrials #InnovativeSolutions #HealthEquity #CommunityEngagement #EmVenioResearch #RealTimeClinicalSolutions

Making clinical trials more accessible is crucial for improving health outcomes in diverse populations and advancing inclusive medical research. Our recent Site Spotlight sheds light on how EmVenio Research is using technology to achieve these goals. In an interview with Phillip Stanford, Senior Director, Applications & PMO at EmVenio, we explore their unique approach and its impact on underrepresented communities. EmVenio is setting up clinical trial sites in areas with limited research activity and leveraging advanced eClinical solutions, like RealTime-SOMS, to break down barriers and ensure diverse participation in clinical research. For a deeper look into EmVenio's innovative work and future plans, read the full interview here: https://lnkd.in/e4pggsYS #SiteSpotlight #DiversityInResearch #ClinicalTrials #InnovativeSolutions #HealthEquity #CommunityEngagement #EmVenioResearch #RealTimeClinicalSolutions

The femtech industry is expected to reach $103 billion by 2030. Motivated by an explosion of companies dedicated to disrupting a historically underserved space, femtech companies are collecting valuable insights to power future developments. Our Partner and Director of the Life Sciences Practice Group, Katherine Rubino, and our Associate, Kasia Zebrowska-Trauben, discussed IP considerations for this emerging market in Inc. Magazine, highlighting the value of developing a robust IP strategy to secure funding. As more and more femtech companies enter the market, leaders will need to establish business objectives early on to protect their transformative innovations and create the most successful IP strategies. Read more advice about the ways IP can protect innovative breakthroughs in life sciences from Kasia and Katherine in Inc.: https://lnkd.in/gGnpQQ_h

10 things I picked up at LSX World Congress London, for healthtech/biotech/medtech sectors: Sector: * Main indices (and new drug approvals) are growing at faster rate, but still 20%+ below 2021 highs, so upside potential * Global market is $1.3trn, could double by 2030; less people ill post pandemic, but population older + better tech treating more illness * Patent expirations increasing + regulation increasing, expected of a fast growing industry * Sector largely pre revs relatively, so value is in IP. Key to hire chief medical/science officer earlier to maintain IP value * As pandemic effects end, greater pressure on profitability and so larger companies are divesting lower performing projects Funding: * US vs Europe converging as both stretch their barometers to compete, but US silicon valley culture more ‘put the money in and run as fast as possible’ (more losses, but comparatively more wins) which could cause overvaluations vs cautious Europe * £500m IPOs used to be boundary pushing, now it’s common with series C, so more complex IPOs needing more DD/advisory/funding/regulation * More scientists in US VC/PE vs more finance in European VC/PE, so more product focus in US vs commercial focus in Europe * US funding good through venture -> growth -> IPO/M&A stage vs Europe which is good at venture + IPO/M&A stage and less so in middle growth stage * SPAC IPOs, a driver of valuation highs seen in 2021 (as target companies could present comparably stronger fwd projections through permissible use of pro forma calculations) are no longer used #TMT #biotech #medtech #healthtech

Making clinical trials more accessible is crucial for improving health outcomes in diverse populations and advancing inclusive medical research. Our recent Site Spotlight sheds light on how EmVenio Research is using technology to achieve these goals. In an interview with Phillip Stanford, Senior Director, Applications & PMO at EmVenio, we explore their unique approach and its impact on underrepresented communities. EmVenio is setting up clinical trial sites in areas with limited research activity and leveraging advanced eClinical solutions, like RealTime-SOMS, to break down barriers and ensure diverse participation in clinical research. For a deeper look into EmVenio's innovative work and future plans, read the full interview here: https://lnkd.in/g_bqah8M #SiteSpotlight #DiversityInResearch #ClinicalTrials #InnovativeSolutions #HealthEquity #CommunityEngagement #EmVenioResearch #RealTimeClinicalSolutions

"Commencing on a journey in the lab business is not just a venture;it's a profound opportunity to serve mankind while making sound financial strides. The healthcare industry is evolving, and laboratories play a crucial role in diagnostics and research. Our commitment is twofold: advancing science for the greater good and ensuring a profitable venture. Lab businesses are not only a gateway to scientific discovery but also a lucrative investment. Join us in this meaningful pursuit where service to humanity aligns seamlessly with financial success. Let's explore the boundless potential of both impact and profit in the realm of laboratory services. 💼🔬💰 #LabBusiness #ProfitableVenture #HealthcareInnovatio #Bloodtestconsultancy

We're thrilled to present a panel discussion at Keiretsu Forum focusing on the latest MedTech and life sciences trends. Accredited investors, this is your chance to engage with industry insiders and gain valuable insights. #KeiretsuForum #VentureCapital #MedTechInnovation